Development Of Reversible Inhibitors Of Factor XIa
Funder
National Health and Medical Research Council
Funding Amount
$444,318.00
Summary
Blood usually clots in response to injury, but unwanted clots can cause thrombosis, as well as leading to stroke and heart disease. Existing drugs to treat thrombosis suffer from drawbacks such as invasive monitoring, interaction with diet and other medicines, and bleeding complications. New drugs are clearly needed. Our expert group of researchers will discover new anti-thrombotic compounds based upon our previous identification of natural products with anticoagulant properties.
Therapeutic Potential Of The Dipeptidyl Peptidase IV Gene Family
Funder
National Health and Medical Research Council
Funding Amount
$478,067.00
Summary
We will further investigate the therapeutic potential of the Dipeptidyl Peptidase (DP) IV gene family by studying genes identified as probable therapeutic targets for stem cell transplant, anti-inflammatory and cancer therapies. DPIV is an identified target for diabetes therapy. Our research group is internationally recognised as expert in both liver disease pathogenesis and the DPIV gene family.